Fosun Pharma announces 2020 annual results: a number of innovations accelerate the implementation

About Fosun Pharma:

Shanghai Fosun Pharmaceutical (Group) Co.
, Ltd.
("Fosun Pharmaceutical" for short, stock code: 600196.
SH, 02196.
HK) was established in 1994.
It is a leading, innovation-driven international pharmaceutical and healthcare industry group in China.
Strategically deploy the pharmaceutical and health industry chain, and directly operate businesses including pharmaceuticals, medical devices and medical diagnosis, and medical services, and cover the pharmaceutical business field through equity participation in Sinopharm Holdings
.

With its pharmaceutical business as its core, Fosun Pharma insists on innovative research and development.
Through independent research and development, cooperative development, license introduction, and in-depth incubation, it focuses on tumor and immune regulation, four highs (hypertension, hyperlipidemia, hyperglycemia, hyperuricemia) Establish and form technology platforms for small molecule innovative drugs, antibody drugs, and cell therapy in key disease areas such as complications and central nervous system, and actively explore cutting-edge technology fields such as targeted protein degradation, RNA, oncolytic viruses, and gene therapy to enhance innovation Ability
.

Facing the future, Fosun Pharma will, under the guidance of the "4IN" (Innovation Innovation, Internationalization, Integration, and Intelligent Intelligentization) strategy, adhering to the development model of "Innovation and Transformation, Integrated Operation, and Steady Growth" and the concept of sustainable development , Is committed to becoming a first-class enterprise in the global mainstream medical and health market
.